Profile data is unavailable for this security.
About the company
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.
- Revenue in USD (TTM)250.73m
- Net income in USD-30.80m
- Incorporated2007
- Employees610.00
- LocationCastle Biosciences Inc505 S Friendswood Drive2014 SAN MIGUEL DRFRIENDSWOOD 77546United StatesUSA
- Phone+1 (281) 796-9032
- Fax+1 (302) 636-5454
- Websitehttps://castlebiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORIC Pharmaceuticals Inc | 0.00 | -101.76m | 606.13m | 102.00 | -- | 1.84 | -- | -- | -1.81 | -1.81 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -35.25 | -33.92 | -37.18 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| Lexicon Pharmaceuticals Inc | 2.31m | -193.58m | 614.46m | 285.00 | -- | 1.45 | -- | 265.88 | -0.8257 | -0.8257 | 0.0098 | 1.17 | 0.008 | -- | 2.59 | 8,108.77 | -66.76 | -24.41 | -72.21 | -29.01 | 94.98 | 98.49 | -8,376.55 | -84.92 | 15.56 | -11.46 | 0.2569 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| PetIQ Inc | 1.12bn | 7.34m | 617.65m | 1.93k | 96.28 | 2.61 | 11.39 | 0.5515 | 0.2156 | 0.2156 | 36.40 | 7.95 | 1.29 | 4.58 | 5.67 | 579,376.60 | 0.8933 | -4.32 | 1.14 | -5.23 | 23.66 | 20.05 | 0.6951 | -3.66 | 1.25 | 1.84 | 0.6517 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
| Cartesian Therapeutics Inc | 25.91m | -254.87m | 617.88m | 38.00 | -- | -- | -- | 23.85 | -48.02 | -48.02 | 4.94 | -21.18 | 0.1077 | -- | 5.86 | 681,736.80 | -106.00 | -43.66 | -122.03 | -66.84 | -- | -- | -983.83 | -136.35 | -- | -0.5249 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Mind Medicine (MindMed) Inc | 0.00 | -125.32m | 632.48m | 57.00 | -- | 3.19 | -- | -- | -2.94 | -2.94 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -58.14 | -- | -73.35 | -- | -- | -- | -- | -- | -- | -- | 0.0675 | -- | -- | -- | -68.55 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -90.80m | 634.01m | 28.00 | -- | 1.93 | -- | -- | -2.18 | -2.18 | 0.00 | 6.61 | 0.00 | -- | -- | 0.00 | -27.78 | -- | -29.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Arbutus Biopharma Corp | 12.99m | -74.39m | 634.09m | 73.00 | -- | 5.28 | -- | 48.83 | -0.4393 | -0.4393 | 0.0766 | 0.6362 | 0.0761 | -- | 5.41 | 177,890.40 | -43.56 | -52.62 | -50.25 | -58.11 | -- | -- | -572.81 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Dianthus Therapeutics Inc | 3.22m | -50.21m | 634.24m | 53.00 | -- | 1.70 | -- | 196.73 | -3.20 | -3.20 | 0.2721 | 12.70 | 0.0138 | -- | -- | 60,830.19 | -21.56 | -41.40 | -22.27 | -44.70 | -- | -- | -1,557.51 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Harrow Inc | 138.68m | -31.33m | 635.11m | 315.00 | -- | 10.49 | -- | 4.58 | -0.9079 | -0.9079 | 4.09 | 1.71 | 0.5406 | 4.21 | 6.75 | 440,244.40 | -12.21 | -10.86 | -13.79 | -12.71 | 69.77 | 70.75 | -22.59 | -15.35 | 2.75 | -0.3302 | 0.7536 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Sinovac Biotech Ltd | 448.27m | -105.90m | 639.90m | 3.04k | -- | -- | -- | 1.43 | -1.08 | -1.08 | 4.19 | 87.41 | 0.0323 | 1.13 | 0.9175 | 147,602.60 | -1.86 | 36.14 | -2.80 | 58.37 | 59.51 | 90.77 | -57.63 | 65.87 | 10.18 | -- | 0.0207 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Taysha Gene Therapies Inc | 14.16m | -118.01m | 641.47m | 52.00 | -- | 11.91 | -- | 45.31 | -1.19 | -1.19 | 0.0896 | 0.2879 | 0.1112 | -- | -- | 272,230.80 | -92.70 | -- | -146.13 | -- | -- | -- | -833.60 | -- | -- | -- | 0.4315 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Castle Biosciences Inc | 250.73m | -30.80m | 642.14m | 610.00 | -- | 1.59 | -- | 2.56 | -1.15 | -1.15 | 9.28 | 14.59 | 0.5664 | 8.01 | 7.12 | 411,024.60 | -6.96 | -9.43 | -7.48 | -10.17 | 80.58 | 80.58 | -12.28 | -28.46 | 9.02 | -- | 0.0243 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Arrivent Biopharma Inc | -100.00bn | -100.00bn | 650.11m | 40.00 | -- | 2.05 | -- | -- | -- | -- | -- | 9.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| AnaptysBio Inc | 22.96m | -163.30m | 654.01m | 117.00 | -- | 13.69 | -- | 28.48 | -6.13 | -6.13 | 0.862 | 1.75 | 0.048 | -- | 5.33 | 196,256.40 | -34.11 | -18.08 | -36.72 | -18.96 | -- | -- | -711.18 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| SAGE Therapeutics Inc | 91.06m | -503.14m | 668.62m | 487.00 | -- | 0.9473 | -- | 7.34 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| National Research Corporation | 147.42m | 30.36m | 670.48m | 435.00 | 22.65 | 18.15 | 18.46 | 4.55 | 1.24 | 1.24 | 6.02 | 1.55 | 1.16 | -- | 11.53 | 338,896.60 | 23.80 | 26.25 | 35.67 | 36.77 | 62.29 | 63.20 | 20.60 | 23.95 | -- | 132.55 | 0.5325 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
Data as of May 31 2024. Currency figures normalised to Castle Biosciences Inc's reporting currency: US Dollar USD
49.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wasatch Advisors LPas of 31 Mar 2024 | 2.55m | 9.29% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.04m | 7.44% |
| Granahan Investment Management, LLCas of 31 Mar 2024 | 1.63m | 5.93% |
| Principal Global Investors LLCas of 31 Mar 2024 | 1.53m | 5.58% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.45m | 5.27% |
| Bellevue Asset Management AGas of 31 Mar 2024 | 1.22m | 4.45% |
| Portolan Capital Management LLCas of 31 Mar 2024 | 1.04m | 3.80% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 749.26k | 2.73% |
| Soleus Capital Management LP (Investment Management)as of 31 Mar 2024 | 725.46k | 2.64% |
| Citadel Advisors LLCas of 31 Mar 2024 | 651.96k | 2.38% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
